Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monroe

Showing results (1071-1080 of 3,505) with videos related to

Pageof 351
Sort By:
Fertility and Sterility|May 1, 1995
Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)L R Nelson, V Y Fujimoto, R B Jaffe, et al.
American Journal of Hematology|July 1, 1993
Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sourcesJ B Lefkowitz, D M Monroe, C K Kasper, et al.
The American Journal of Otology|July 1, 1996
Normal evoked otoacoustic emissions with a profound hearing loss due to a juvenile pilocytic astrocytomaJ A Monroe, L Krauth, I K Arenberg, et al.
The Journal of Clinical Endocrinology and Metabolism|November 1, 1992
Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal womenJ Rabinovici, P Rothman, S E Monroe, et al.
Biochemistry|March 10, 1992
Reversibility of the covalent reaction of CC-1065 and analogues with DNAM A Warpehoski, D E Harper, M A Mitchell, et al.
European Journal of Pharmacology|January 5, 1995
Opioid effects on spinal [3H]5-hydroxytryptamine release are not related to their antinociceptive actionP J Monroe, B K Kradel, D L Smith, et al.
Ocular Immunology and Inflammation|February 26, 2014
Sclerouveitis associated with Rosai-Dorfman disease in an HIV-infected patientAnne K Monroe, Bryn M Burkholder, Nicholas J Butler, et al.
Applied and Environmental Microbiology|December 3, 2004
Genogroup I and II noroviruses detected in stool samples by real-time reverse transcription-PCR using highly degenerate universal primersGary P Richards, Michael A Watson, Rebecca L Fankhauser, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 1, 2024
Trends in the Uptake of Index Testing Among Adolescents in USAID-Supported President's Emergency Plan for AIDS Relief Programs, October 2017-September 2022Tishina Okegbe, Kristina Monroe Bishop, Jessica Rose, et al.
The Journal of Pain|September 26, 2024
Psychologically Informed Physical Therapy Management of Chronic Musculoskeletal Pain in Culturally Diverse Populations: An Intervention Logic ModelKatrina S Monroe, Kristin R Archer, Stephen T Wegener, et al.
Pageof 351

Showing results (1071-1080 of 3,505) with videos related to

Sort By:
Pageof 351
Fertility and Sterility|May 1, 1995
Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)L R Nelson, V Y Fujimoto, R B Jaffe, et al.
American Journal of Hematology|July 1, 1993
Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sourcesJ B Lefkowitz, D M Monroe, C K Kasper, et al.
The American Journal of Otology|July 1, 1996
Normal evoked otoacoustic emissions with a profound hearing loss due to a juvenile pilocytic astrocytomaJ A Monroe, L Krauth, I K Arenberg, et al.
The Journal of Clinical Endocrinology and Metabolism|November 1, 1992
Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal womenJ Rabinovici, P Rothman, S E Monroe, et al.
Biochemistry|March 10, 1992
Reversibility of the covalent reaction of CC-1065 and analogues with DNAM A Warpehoski, D E Harper, M A Mitchell, et al.
European Journal of Pharmacology|January 5, 1995
Opioid effects on spinal [3H]5-hydroxytryptamine release are not related to their antinociceptive actionP J Monroe, B K Kradel, D L Smith, et al.
Ocular Immunology and Inflammation|February 26, 2014
Sclerouveitis associated with Rosai-Dorfman disease in an HIV-infected patientAnne K Monroe, Bryn M Burkholder, Nicholas J Butler, et al.
Applied and Environmental Microbiology|December 3, 2004
Genogroup I and II noroviruses detected in stool samples by real-time reverse transcription-PCR using highly degenerate universal primersGary P Richards, Michael A Watson, Rebecca L Fankhauser, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 1, 2024
Trends in the Uptake of Index Testing Among Adolescents in USAID-Supported President's Emergency Plan for AIDS Relief Programs, October 2017-September 2022Tishina Okegbe, Kristina Monroe Bishop, Jessica Rose, et al.
The Journal of Pain|September 26, 2024
Psychologically Informed Physical Therapy Management of Chronic Musculoskeletal Pain in Culturally Diverse Populations: An Intervention Logic ModelKatrina S Monroe, Kristin R Archer, Stephen T Wegener, et al.
Pageof 351